Novo Cure LTD NVCR
We take great care to ensure that the data presented and summarized in this overview for NovoCure Ltd is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVCR
View all-
Black Rock Inc. New York, NY12.1MShares$232 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$226 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA8.87MShares$170 Million0.05% of portfolio
-
Capital World Investors Los Angeles, CA4.82MShares$92.2 Million0.02% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.74MShares$52.5 Million5.68% of portfolio
-
State Street Corp Boston, MA2.64MShares$50.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.4MShares$46 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.69MShares$32.4 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.68MShares$32.2 Million0.01% of portfolio
-
Northern Trust Corp Chicago, IL1.28MShares$24.6 Million0.01% of portfolio
Latest Institutional Activity in NVCR
Top Purchases
Top Sells
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Insider Transactions at NVCR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2025
|
Ashley Cordova Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
151,181
+29.86%
|
$2,721,258
$18.19 P/Share
|
|
Mar 04
2025
|
Mukund Paravasthu Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+39.52%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+21.68%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+19.9%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Michal Nath Puri Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+25.14%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+24.04%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Nicolas Leupin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+34.34%
|
$989,550
$18.19 P/Share
|
|
Mar 04
2025
|
Christoph Brackmann Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,975
+31.21%
|
$989,550
$18.19 P/Share
|
|
Mar 03
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
250
-0.85%
|
$4,500
$18.54 P/Share
|
|
Mar 03
2025
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,053
-1.0%
|
$36,954
$18.54 P/Share
|
|
Mar 03
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
2,527
-1.73%
|
$45,486
$18.54 P/Share
|
|
Mar 03
2025
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
268
-0.16%
|
$4,824
$18.92 P/Share
|
|
Feb 28
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
368
-1.24%
|
$6,624
$18.28 P/Share
|
|
Feb 28
2025
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,341
-1.12%
|
$42,138
$18.28 P/Share
|
|
Feb 28
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
2,770
-1.86%
|
$49,860
$18.28 P/Share
|
|
Feb 28
2025
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
4,637
-1.36%
|
$83,466
$18.55 P/Share
|
|
Feb 27
2025
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,646
-2.64%
|
$32,920
$20.24 P/Share
|
|
Feb 27
2025
|
Ashley Cordova Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,153
-2.56%
|
$223,060
$20.24 P/Share
|
|
Feb 27
2025
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
12,266
-3.85%
|
$245,320
$20.24 P/Share
|
|
Feb 27
2025
|
Michal Nath Puri Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,387
-0.63%
|
$27,740
$20.24 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.01M shares |
|---|---|
| Exercise of conversion of derivative security | 124K shares |
| Open market or private sale | 50K shares |
|---|